The Zeta Agenda: The Zetas don’t just want our planet — they want our bodies to incarnate in, but our present DNA does not resonate with their Soul group. / DEADLY SHOTS! Former Pfizer Employee Confirms Poison in COVID ‘Vaccine’ / ‘Recipes for Regulatory Corruption’: How CDC, NIH Pull in Millions From Licensing Deals, Including COVID-Related Technologies / Dane Wigington: GRAPHENE SKIES?

Graphene Oxide

VSF: The Alien Invasion Agenda includes the creation of the corporate model. Corporations have now taken over our planet. We live in what some have termed a Corporatocracy. In my understanding, the military industrial complex now consists of corporations that are controlled at the top levels by the Draco Reptilians and the Zeta Reticuli Greys.

The pharmaceutical corporations are also controlled by the Alien Invasion Agenda. This means that ‘Big Pharma’ is in fact the instrument of the invaders. For many years prescription drugs have been used to destroy the human immune system. While these drugs may provide some temporary relief — they never cure or address the source. An increasing plethora of prescription drugs all contain warnings “side effects include” and unlike herbal remedies, tend to weaken our defenses, and in the long run making us sicker. How many friends and loved one do you personally know who are addicted to their prescriptions? It would be unprofitable for you to actually get well!

The ‘jab’ is an escalation of this intent to remove the Human Angelic soul group from our planet. The mRNA technology has nothing to do with a cure —- but rather is a way to modify our genes and make the human body more suitable to the soul group of the Zeta Greys.

DEADLY SHOTS! Former Pfizer Employee Confirms Poison in COVID ‘Vaccine’

Rumble — EXCLUSIVE! Karen Kingston, a former Pfizer employee and current analyst for the pharmaceutical and medical device industries, came forward with indisputable documentation that should be shared with the ENTIRE WORLD!

The inoculation being referred to as ‘COVID Vaccines’ is a poisonous death sentence, and nobody should subject themselves to the shots.

VSF: Read this article to understand the depth of the corruption that has overtaken our medical care system.

Recipes for Regulatory Corruption’: How CDC, NIH Pull in Millions From Licensing Deals, Including COVID-Related Technologies
Aggregated data for fiscal year 2020 show the NIH and CDC collected a combined $63.4 million in royalty revenues under a business model that allows the NIH to grant technology licenses to the private sector.
By Children’s Health Defense Team

With 27 different institutes and centers housed under the National Institutes of Health (NIH) umbrella — including the National Institute for Allergy and Infectious Diseases (NIAID)  — NIH is the largest biomedical research agency in the world.
Operating under the U.S. Department of Health and Human Services (HHS), NIH currently wields a hefty annual budget of nearly $42 billion.
Within NIH, the Office of Technology Transfer (OTT) plays a “strategic role” in supporting patenting and licensing for inventions that emerge from laboratories at the NIH and also Centers for Disease Control and Prevention (CDC).
In a win-win business model, the NIH routinely grants technology licenses (both exclusive and non-exclusive) to the private sector for use or commercialization of its inventions, with those licenses then driving billions of dollars in royalties back into NIH coffers.
In fiscal year (FY) 2020 alone — October 2019 through September 2020 — aggregated data for NIH and CDC show the agencies collected a neat $63.4 million in royalty revenues.
Under federal law, a portion of licensing royalties reverts to NIH to support undefined “mission-related activities.” Another portion goes directly to the agency’s inventors, who are allowed up to $150,000 in payments per calendar year. The same holds true at CDC.
Scientists like to frame these payments as “positive incentives,” but Children’s Health Defense Chairman Robert F. Kennedy, Jr. characterizes the royalty rules as “recipes for regulatory corruption.”
Tell Schools/Universities No Vaccine Mandates for Children/Young Adults!
The gift that keeps on giving
Universities, too, receive royalties when they market patented technologies. Nearly 25 years ago, a University of Michigan biologist complained that two California universities (both public and private) were using royalties as a mechanism to covertly fleece taxpayers.
Citing a technology patented and licensed by the two universities, the professor explained that “ordinary people” had already paid through their tax dollars for the basic research that gave rise to the patents. He argued taxpayers should not have to continue paying the universities “many times over the original investment through patent royalties.”
The royalty monies flowing to NIH scientists have periodically attracted comparable public ire.
In 2005, an explosive Associated Press (AP) scoop showed large numbers of agency scientists — at the NIH’s explicit instruction — were routinely failing to disclose royalty payments, either to taxpayers or to participants in taxpayer-funded clinical trials who were obligingly testing out the NIH’s royalty-generating experimental treatments.
As AP pointed out, “Such research helps bring the treatment closer to possible commercial use, which could in turn bring the researchers and NIH higher royalties.”
Among the scientists scolded by AP for “testing products for which they secretly receive[d] royalties” was NIAID’s Dr. Anthony Fauci.
Even without royalties (which are classified as “federal compensation” rather than “outside income”), the long-time NIAID director — who describes himself as a humble “government worker” with a “government salary” — is the nation’s highest paid federal employee.
During the 2005 brouhaha, professing to be “extremely sensitive about the possibility of an appearance of a conflict of interest,” Fauci told the public he was donating his payments to charity.
Judging by a late-2020 report from the Government Accountability Office (GAO), there is still considerable room for improvement in terms of NIH transparency about NIH’s  licensing activities.
The GAO noted NIH “does not report which of its patents are licensed or release metrics that would enable the public to evaluate how licensing affects patient access to resulting drugs.”
As one of its top two recommendations, the GAO urged NIH to provide “more information to the public” — in “an accessible and searchable format to the maximum extent possible” — to help citizens and policymakers understand licensing outcomes and impacts.
2020: Laying the groundwork for more historic highs?
“More public information” is conspicuously lacking in the OTT’s FY2020 annual report, which provides only one paragraph of specifics (and two paragraphs of boilerplate) in a short section on “Inventions and Agreements.”
In addition to noting the $63.4 million in FY2020 royalty revenues, the paragraph highlights a significant uptick in invention disclosures (up 20% over FY2019) and patent applications — 47% more applications filed compared to the previous year. (Invention disclosures are the first step in the patenting process.)
Elsewhere, technology transfer statistics show NIH executed more licenses in FY2020 (n=359) than in any prior fiscal year dating back to 1985 (when a mere 25 licenses were executed).
A few more COVID-specific details are available in the three-page portion of the GAO report focused on NIAID (pp. 22-25). There, we learn NIAID and its Technology Transfer and Intellectual Property Office (TTIPO) worked “diligently” and “as quickly as possible” in 2020 to facilitate worldwide “sharing” of NIAID-developed SARS-CoV-2 spike proteins and plasmids (molecules encoding the spike proteins) to spur development of COVID-19 diagnostics, treatments and vaccines.
These efforts resulted in:
• Ninety-six agreements with 75 academic organizations, nonprofit entities, government agencies, international organizations and other entities to furnish NIAID spike proteins or plasmids for research projects (called “material transfer agreements”)
• Twenty-one licenses negotiated with biotechnology or pharmaceutical companies, mostly for SARS-CoV-2 vaccine development — these licenses pertain to “most of the vaccines in advanced clinical trials and several currently in use around the world” (notably, the Moderna mRNA-1273 vaccine that received Emergency Use Authorization in Dec. 2020)
• An additional 16 agreements to collaborate on research, including four clinical trial agreements for SARS-CoV-2 vaccines
NIH royalty income reached a historic high of $147 million in FY2015. At that time, however, the agency accurately forecast declines beginning around FY2018 due to expiring patents on major products.
Given the COVID-related licensing groundwork laid in FY2020, it would not be surprising to see NIH’s royalties surge anew in FY2021.
Pfizer’s COVID vaccine collaborator, BioNTech, is already paying royalties for use of the NIH-developed spike protein technology. Moderna, which co-owns its COVID vaccine patents with NIAID, is not paying royalties.
CDC’s webpage listing technologies available for licensing (and, therefore, with the potential to generate royalties) has not been updated since May, 2020. At that time, the agency had about 60 technologies on offer, many related to diagnostics or vaccine development.
Whenever the CDC gets around to updating its list, it is likely the number of available technologies will be even higher.
The pandemic growth model
Where public health agencies are concerned, COVID-19 appears to be very good for business, with a flurry of unprecedented funding — conveniently mobilized by the pandemic — ushering in profound and likely permanent changes in a public health infrastructure once lamented as weak and fragmented.
The CDC now brags about having marshaled the largest response effort in its 74-year history. According to the agency’s chief financial officer, “More resources were entrusted to CDC for execution and management [in FY2020] than ever before” — including a more than doubling of the previous year’s funding.
Two-thirds (66%) of the grant funds committed or spent by CDC in FY2020 were COVID-19-related.
Over at NIH, prospects are even rosier for the agency — and scarier for the public. For FY2022, the Biden administration has requested a 21% NIH budget increase (to $51 billion), “accelerating a six-year trend of multi-billion-dollar annual budget increases.”
Most of this would go toward the creation of a new NIH agency that would merge national security with health security, modeled after the military’s Defense Advanced Research Projects Agency (DARPA).
Knowing of DARPA’s disturbing track record, investigative journalist Whitney Webb characterizes the new agency’s security mandate as “a recipe for a technocratic ‘pre-crime’ organization with the potential to criminalize both mental and physical illness as well as ‘wrongthink.’”
Ironically, many of the COVID therapies proven effective by frontline doctors but actively suppressed by federal agencies are inexpensive — a far cry from the budget-busting experimental vaccines that have been illegitimately framed as the pandemic’s sole solution.
For the public, a major advantage of these therapies — including longtime fixtures on the World Health Organization essential medicines list — is the fact that their safety profile, side effects, dosing and drug interactions are well documented.
However, royalty-hungry scientists are not interested in “tried-and-true, classical … repurposing [of] drugs and strategies that have already been shown to work.” They prefer, in the words of Columbia University’s Dr. Ian Lipkin, novel treatments that are “sexy and new and patentable.”
In short, off-patent drugs like ivermectin and hydroxychloroquine, and cheap supplements like vitamin C and vitamin D — often preventive as well as therapeutic — don’t generate royalties.
Nor do they mesh with the global control agenda the NIH’s new DARPA-like agency promises to facilitate. It is up to the public to reassert, strongly, that people and freedom come first.

From Dane Wigington –

Toxicity of graphene-family nanoparticles: a general review of the origins and mechanisms
• Lingling Ou,
• Bin Song,
• Huimin Liang,
• Jia Liu,
• Xiaoli Feng,
• Bin Deng,
• Ting Sun &
• Longquan Shao 

… several typical mechanisms underlying GFN toxicity have been revealed, for instance, physical destruction, oxidative stress, DNA damage, inflammatory response, apoptosis, autophagy, and necrosis …

GFNs can be delivered into bodies by intratracheal instillation [30], oral administration [31], intravenous injection [32], intraperitoneal injection [33] and subcutaneous injection …

GFNs can induce acute and chronic injuries in tissues by penetrating through the blood-air barrier, blood-testis barrier, blood-brain barrier, and blood-placenta barrier etc. and accumulating in the lung, liver, and spleen etc. …

… graphene nanomaterials aerosols can be inhaled and substantial deposition in the respiratory tract, and they can easily penetrate through the tracheobronchial airways …

The toxicological mechanisms of GFNs demonstrated in recent studies mainly contain inflammatory response, DNA damage, apoptosis, autophagy and necrosis etc. …

GO can result in acute inflammation response and chronic injury …

Fibrosis and inflammation …

The GFNs exert different toxicological effects on male or female reproductive system. pregnant mice had abortions at all dose, and most pregnant mice died when the high dose …

The developmental toxicity of GFNs may induce structural abnormalities, growth retardation, behavioural and functional abnormalities, and even death. …

The cytotoxicity of GFNs in vitro has been verified in various cells to change the cell viability and morphology, destroy the membrane integrity, and induce DNA damage [110–112]. GO or rGO decrease cell adhesion; induce cell apoptosis; and enter lysosomes, mitochondria, cell nuclei, and endoplasm [113]. GQDs entered cells and induced DNA damage …

Graphene can increase cell viability [117] or cause cell death …

… cause dose-dependent toxicity … The high content of GO mainly deposited in the lungs, liver, spleen, and kidneys and was difficult to be cleaned by the kidneys …

Increasing concentrations of GO entered the lysosomes, mitochondria, endoplasm, and cell nucleus …

GO can insert between the base pairs of double-stranded DNA and disturb the flow of genetic information at the molecular level, which might be one of the main causes of the mutagenic effect of GO …

… the importance of the GO surface charge because of its ability to affect the internalization and uptake mechanism of cells …

… strong electrostatic interactions between the negatively charged oxygen groups on the GO/GS surface and positively charged phosphatidylcholine lipids on the RBC outer membrane …

The physical interaction of graphene nanoparticles with cell membranes is one of the major causes of graphene cytotoxicity …

… the sharpened edges of GNS may act as ‘blades’, inserting and cutting through bacterial cell membranes …

… overwhelm the activity of antioxidant enzymes, including catalase, SOD, or glutathione peroxidase (GSH-PX) … The interactions of GO with cells can lead to excessive ROS generation, which is the first step in the mechanisms of carcinogenesis, ageing, and mutagenesis …

Exposure to GFNs resulted in significantly increased coupled and uncoupled mitochondrial oxygen consumption, dissipation of the mitochondrial membrane potential, and eventual triggering of apoptosis by activating the mitochondrial pathway …

GFNs can cause apoptosis and/or cell necrosis by direct influencing cell mitochondrial activity …

Due to its small size, high surface area and surface charge, GO may possess significant genotoxic properties and cause severe DNA damage, for example, chromosomal fragmentation, DNA strand breakages, point mutations, and oxidative DNA adducts and alterations …

Even if GO cannot enter into the nucleus of a cell, it may still interact with DNA during mitosis when the nuclear membrane breaks down, which increases the opportunity for DNA aberrations …

The π stacking interaction between the graphene carbon rings and the hydrophobic DNA base pairs can make a DNA segment ‘stand up’ or ‘lay on’ the surface of graphene with its helical axis perpendicular or parallel, respectively. The intermolecular forces severely deform the end base pairs of DNA, which potentially increases the genotoxicity …

DNA damage can not only initiate cancer development but also possibly threaten the health of the next generation if the mutagenic potential of GO arises in reproductive cells, which impacts fertility and the health of offspring …

A strong inflammatory response was induced by subcutaneously injection …

Apoptosis is defined as the self-destruction of a cell regulated by genes through complicated programmes … after inhalation …

… graphene and GO physically damaged cell membranes … increased the permeabilization of the outer mitochondrial membrane and changed the mitochondrial membrane potential … triggered by the death-receptor and canonical mitochondrial pathway …

Necrosis is an alternate form of cell death induced by inflammatory responses or cellular injury. The exposure of cells to pristine graphene causes apoptosis and necrosis at high doses …

GFNs could cause subtle changes in gene expression programming by modulating epigenetic changes.

This entry was posted in Uncategorized. Bookmark the permalink.